"In the neoadjuvant setting, Kato et al. explored the impact of neoadjuvant androgen deprivation therapy (ADT) in high-risk PCa patients with concurrent IDC-P [43]. They retrospectively analyzed 145 patients post-RP, stratifying them into three groups: IDC-P-negative, IDC-P-positive with disappearance post-ADT, and IDC-P-positive with persistence post-ADT. Interestingly, around 28% of IDC-P-positive cases responded to ADT, exhibiting the complete disappearance of IDC-P at RP and demonstrating comparable overall survival to IDC-P-negative cases. Conversely, the remaining 72% with persistent IDC-P showed the worst prognosis, with a hazard ratio of 3.84 compared to IDC-P-negative cases. "
I really do not understand why all of the findings and research mean nothing until they become "standard of care" which may happen never or 15 years later when it is meaningless for patients that are having a problem NOW .
The whole process of PC treatment is "up to a patient" anyways, so why those patients do not have a right to try some individualized approach with signing non liability papers for doctors ?! Why, for example, my husband was never informed of neoadjuvant approach for IDC ? Adding ADT before treatment is definitely not unheard of approach nor controversial in any shape or form . Here would be no harm done and he would possibly even have his IDC completely disappear before RP !
The more I learn about what could have been done for my husband and was not , the more depressing it is becoming. It is one thing when one just has a bad luck end ends with difficult situation and the whole another level of unfortunate when that situation was preventable or helped in significant way but was not 😢.
I don’t want to come across as the guy saying “don’t worry,” because believe me, I am extremely worried. But I think there are a few things to keep in mind with the Kato study. It was done on men who had surgery between 1991 and 2005 — that’s a very long time ago in prostate cancer terms. A lot of the tools we take for granted now simply didn’t exist back then: ultrasensitive PSA testing, PSMA PET imaging, and protocols for very early salvage radiation. Salvage in that era often meant “late salvage,” which we now know is a different story altogether.
It’s also a retrospective analysis, so who got how much ADT, who got follow-up, and how salvage was timed weren’t standardized. That makes the outcomes harder to interpret. Add in the fact that randomized controlled trials since then (RADICALS, GETUG, RAVES) have shown early salvage can match adjuvant without the same toxicity, and the picture looks more complicated.
None of that means IDC or cribriform patterns aren’t scary — they absolutely are. For me, the takeaway isn’t to relax, but to push for heightened vigilance: ultrasensitive PSA every three months, acting on even small rises, and making sure Decipher and imaging are part of the discussion. I don’t want to minimize anyone’s worry — I share it — but I think the real battle is making sure we don’t miss our window with the tools and evidence we have now.